Cargando…

Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country

Type 2 diabetes mellitus (T2DM) is increasingly known as a risk factor of hepatocellular carcinoma (HCC). In this study, we determined the risk factors associated with HCC in T2DM patients. This was a matched case-control study conducted at two hepatobiliary referral centres in a developing country....

Descripción completa

Detalles Bibliográficos
Autores principales: Azit, Noor Atika, Sahran, Shahnorbanun, Voon Meng, Leow, Subramaniam, Manisekar, Mokhtar, Suryati, Mohammed Nawi, Azmawati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659343/
https://www.ncbi.nlm.nih.gov/pubmed/34882716
http://dx.doi.org/10.1371/journal.pone.0260675
_version_ 1784612942641102848
author Azit, Noor Atika
Sahran, Shahnorbanun
Voon Meng, Leow
Subramaniam, Manisekar
Mokhtar, Suryati
Mohammed Nawi, Azmawati
author_facet Azit, Noor Atika
Sahran, Shahnorbanun
Voon Meng, Leow
Subramaniam, Manisekar
Mokhtar, Suryati
Mohammed Nawi, Azmawati
author_sort Azit, Noor Atika
collection PubMed
description Type 2 diabetes mellitus (T2DM) is increasingly known as a risk factor of hepatocellular carcinoma (HCC). In this study, we determined the risk factors associated with HCC in T2DM patients. This was a matched case-control study conducted at two hepatobiliary referral centres in a developing country. Patients’ sociodemographic, clinical, and biochemical characteristics between 1 January 2012 and 30 June 2018 were extracted from the electronic medical records and analysed using multivariate logistic regression analysis. A total of 212 case-control pairs were included. Significant risk factors included Chinese and Malay ethnicities that interacted with viral hepatitis (adjusted odds ratio [AOR] = 11.77, 95% confidence interval [CI]: 1.39–99.79) and (AOR = 37.94, 95% CI: 3.92–367.61) respectively, weight loss (AOR = 5.28, 95% CI: 2.29–12.19), abdominal pain/ discomfort (AOR = 6.73, 95% CI: 3.34–13.34), alcohol (AOR = 4.08, 95% CI: 1.81–9.22), fatty liver (AOR = 3.29, 95% CI: 1.40–7.76), low platelet (AOR = 4.03, 95% CI:1.90–8.55), raised alanine transaminase (AOR = 2.11, 95% CI: 1.16–3.86). and alkaline phosphatase (ALP) levels (AOR = 2.17, 95% CI: 1.17–4.00). Statins reduced the risk of HCC by 63% (AOR = 0.37, 95% CI: 0.21–0.65). The identification of these factors aids the risk stratification for HCC among T2DM patients for early detection and decision-making in patient management in the primary care setting.
format Online
Article
Text
id pubmed-8659343
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-86593432021-12-10 Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country Azit, Noor Atika Sahran, Shahnorbanun Voon Meng, Leow Subramaniam, Manisekar Mokhtar, Suryati Mohammed Nawi, Azmawati PLoS One Research Article Type 2 diabetes mellitus (T2DM) is increasingly known as a risk factor of hepatocellular carcinoma (HCC). In this study, we determined the risk factors associated with HCC in T2DM patients. This was a matched case-control study conducted at two hepatobiliary referral centres in a developing country. Patients’ sociodemographic, clinical, and biochemical characteristics between 1 January 2012 and 30 June 2018 were extracted from the electronic medical records and analysed using multivariate logistic regression analysis. A total of 212 case-control pairs were included. Significant risk factors included Chinese and Malay ethnicities that interacted with viral hepatitis (adjusted odds ratio [AOR] = 11.77, 95% confidence interval [CI]: 1.39–99.79) and (AOR = 37.94, 95% CI: 3.92–367.61) respectively, weight loss (AOR = 5.28, 95% CI: 2.29–12.19), abdominal pain/ discomfort (AOR = 6.73, 95% CI: 3.34–13.34), alcohol (AOR = 4.08, 95% CI: 1.81–9.22), fatty liver (AOR = 3.29, 95% CI: 1.40–7.76), low platelet (AOR = 4.03, 95% CI:1.90–8.55), raised alanine transaminase (AOR = 2.11, 95% CI: 1.16–3.86). and alkaline phosphatase (ALP) levels (AOR = 2.17, 95% CI: 1.17–4.00). Statins reduced the risk of HCC by 63% (AOR = 0.37, 95% CI: 0.21–0.65). The identification of these factors aids the risk stratification for HCC among T2DM patients for early detection and decision-making in patient management in the primary care setting. Public Library of Science 2021-12-09 /pmc/articles/PMC8659343/ /pubmed/34882716 http://dx.doi.org/10.1371/journal.pone.0260675 Text en © 2021 Azit et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Azit, Noor Atika
Sahran, Shahnorbanun
Voon Meng, Leow
Subramaniam, Manisekar
Mokhtar, Suryati
Mohammed Nawi, Azmawati
Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country
title Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country
title_full Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country
title_fullStr Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country
title_full_unstemmed Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country
title_short Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country
title_sort risk factors of hepatocellular carcinoma in type 2 diabetes patients: a two-centre study in a developing country
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659343/
https://www.ncbi.nlm.nih.gov/pubmed/34882716
http://dx.doi.org/10.1371/journal.pone.0260675
work_keys_str_mv AT azitnooratika riskfactorsofhepatocellularcarcinomaintype2diabetespatientsatwocentrestudyinadevelopingcountry
AT sahranshahnorbanun riskfactorsofhepatocellularcarcinomaintype2diabetespatientsatwocentrestudyinadevelopingcountry
AT voonmengleow riskfactorsofhepatocellularcarcinomaintype2diabetespatientsatwocentrestudyinadevelopingcountry
AT subramaniammanisekar riskfactorsofhepatocellularcarcinomaintype2diabetespatientsatwocentrestudyinadevelopingcountry
AT mokhtarsuryati riskfactorsofhepatocellularcarcinomaintype2diabetespatientsatwocentrestudyinadevelopingcountry
AT mohammednawiazmawati riskfactorsofhepatocellularcarcinomaintype2diabetespatientsatwocentrestudyinadevelopingcountry